OTLK
OTLK
NASDAQ · Biotechnology

Outlook Therapeutics Inc

$1.59
-0.10 (-5.92%)
As of Jun 30, 10:45 PM ET ·
Financial Highlights (FY 2026)
Revenue
6.62M
Net Income
-292,346,966
Gross Margin
4.0%
Profit Margin
-4,416.2%
Rev Growth
-22.9%
D/E Ratio
1.25
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 4.0% 4.0% 56.9% 56.9%
Operating Margin -4,744.2% -4,269.8% -19.4% -22.9%
Profit Margin -4,416.2% -4,195.4% -21.7% -24.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 6.62M 8.58M 5.83M 5.25M
Gross Profit 268.0K 347.7K 3.32M 2.99M
Operating Income -313,883,710 -366,543,841 -1,128,182 -1,200,249
Net Income -292,346,966 -341,393,887 -1,267,217 -1,265,078
Gross Margin 4.0% 4.0% 56.9% 56.9%
Operating Margin -4,744.2% -4,269.8% -19.4% -22.9%
Profit Margin -4,416.2% -4,195.4% -21.7% -24.1%
Rev Growth -22.9% -22.9% +8.5% -2.3%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 77.44M 77.44M 11.21M 13.12M
Total Equity 61.89M 61.89M 16.90M 15.49M
D/E Ratio 1.25 1.25 0.66 0.85
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -313,515,233 -386,453,187 -1,820,131 -1,644,658
Free Cash Flow -1,133,887 -1,157,439